Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial

Annals of Internal Medicine

Volumn 161, Issue 4, 2014, Pages 249-260

  Harman, S Mitchell ^a   Black, Dennis M ^b   Naftolin, Frederick ^c   Brinton, Eliot A ^d   Budoff, Matthew J ^e   Cedars, Marcelle I ^f   Hopkins, Paul N ^d   Lobo, Rogerio A ^g   Manson, Joann E ^h   Merriam, George R ⁿ   Miller, Virginia M ⁱ   Neal Perry, Genevieve ^j   Santoro, Nanette ^k   Taylor, Hugh S ^l   Vittinghoff, Eric ^b   Yan, Mingzhu ^m   Hodis, Howard N ^m  

^a Phoenix Veterans Affairs Health Care System   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e St John's Cardiovascular Research Center   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Obstetrics and Gynecology Columbia University College of Physicians and Surg ^*  (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ MAYO GRADUATE SCHOOL   (United States)

^j ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF COLORADO   (United States)

^l YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; PROGESTERONE; SEX HORMONE BINDING GLOBULIN; LIPID;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CAROTID ARTERY INTIMA MEDIA THICKNESS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; DISEASE COURSE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; EARLY MENOPAUSE; ECHOGRAPHY; ESTROGEN BLOOD LEVEL; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; IMAGE ANALYSIS; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MENOPAUSAL HORMONE THERAPY; MENOPAUSE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFECTS; ESTROGEN THERAPY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; POSTMENOPAUSE; RADIOGRAPHY; RISK FACTOR;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INSULIN RESISTANCE; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN;

EID: 84907348536     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-0353     Document Type: Article

References (59)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:188-97. [PMID: 22215894] doi:10.1161/CIR.0b013e3182456d46
2. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208. [PMID: 7807658]
3. Herrington DM, Werbel BL, Riley WA, Pusser BE, Morgan TM. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol. 1999;33:2030-7. [PMID: 10362210]
4. Futterman LG, Lemberg L. Lp(a) lipoprotein-an independent risk factor for coronary heart disease after menopause. Am J Crit Care. 2001;10:63-7. [PMID: 11153187]
5. Störk S, von Schacky C, Angerer P. The effect of 17β-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis. 2002;165:301-7. [PMID: 12417281]
6. Guzic-Salobir B, Keber I, Seljeflot I, Arnesen H, Vrabic L. Combined hormone replacement therapy improves endothelial function in healthy postmenopausal women. J Intern Med. 2001;250:508-15. [PMID: 11902819]
7. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation. 2001;104:1773-8. [PMID: 11591613]
8. Kawecka-Jaszcz K, Czarnecka D, Olszanecka A, Rajzer M, Jankowski P. The effect of hormone replacement therapy on arterial blood pressure and vascular compliance in postmenopausal women with arterial hypertension. J Hum Hypertens. 2002;16:509-16. [PMID: 12080436]
9. Moreau KL, Donato AJ, Seals DR, DeSouza CA, Tanaka H. Regular exercise, hormone replacement therapy and the age-related decline in carotid arterial compliance in healthy women. Cardiovasc Res. 2003;57:861-8. [PMID: 12618248]
10. Harvey PJ, Wing LM, Savage J, Molloy D. The effects of different types and doses of oestrogen replacement therapy on clinic and ambulatory blood pressure and the renin-angiotensin system in normotensive postmenopausal women. J Hypertens. 1999;17:405-11. [PMID: 10100079]
11. Scuteri A, Bos AJ, Brant LJ, Talbot L, Lakatta EG, Fleg JL. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med. 2001;135:229-38. [PMID: 11511137]
12. Steiner AZ, Hodis HN, Lobo RA, Shoupe D, Xiang M, Mack WJ. Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: the Estrogen in the Prevention of Atherosclerosis Trial. Menopause. 2005;12:728-33. [PMID: 16278616]
13. Ichikawa J, Sumino H, Ichikawa S, Ozaki M. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens. 2006;19:744-9. [PMID: 16814131]
14. Bush TL, Cowan LD, Barrett-Connor E, Criqui MH, Karon JM, Wallace RB, et al. Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA. 1983;249:903-6. [PMID: 6823043]
15. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-62. [PMID: 1870648]
16. Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol. 1996;87:6-12. [PMID: 8532268]
17. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-41. [PMID: 11119394]
18. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33. [PMID: 12117397]
19. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-34. [PMID: 12904517]
20. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-12. [PMID: 15082697]
21. Hsia J, Criqui MH, Rodabough RJ, Langer RD, Resnick HE, Phillips LS, et al; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative. Circulation. 2004;109:620-6. [PMID: 14769684]
22. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med. 2003;348:645-50. [PMID: 12584376]
23. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310:1353-68. [PMID: 24084921] doi: 10.1001/jama.2013.278040
24. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308:1583-7. [PMID: 15947175]
25. Naftolin F, Taylor HS, Karas R, Brinton E, Newman I, Clarkson TB, et al; Women's Health Initiative. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril. 2004;81:1498-501. [PMID: 15193467]
26. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause. 2007;14:373-84. [PMID: 17438515]
27. Brinton EA, Hodis HN, Merriam GR, Harman SM, Naftolin F. Can menopausal hormone therapy prevent coronary heart disease? Trends Endocrinol Metab. 2008;19:206-12. [PMID: 18450469] doi:10.1016/j.tem.2008.03.002
28. Harman SM, Brinton EA. Biphasic effects of hormone treatment on risk of cardiovascular disease: Resolving the paradox in postmenopausal women. Menopausal Med. 2009;17:S5-8.
29. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al; Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166: 357-65. [PMID: 16476878]
30. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-77. [PMID: 17405972]
31. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al; WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356:2591-602. [PMID: 17582069]
32. Arad Y, Spadaro LA, Goodman K, Lledo-Perez A, Sherman S, Lerner G, et al. Predictive value of electron beam computed tomography of the coronary arteries. 19-month follow-up of 1173 asymptomatic subjects. Circulation. 1996; 93:1951-3. [PMID: 8640967]
33. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262-9. [PMID: 9471928]
34. Kennedy J, Shavelle R, Wang S, Budoff M, Detrano RC. Coronary calcium and standard risk factors in symptomatic patients referred for coronary angiography. Am Heart J. 1998;135:696-702. [PMID: 9539488]
35. Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001;104:1863-7. [PMID: 11591627]
36. Raggi P, Cooil B, Shaw LJ, Aboulhson J, Takasu J, Budoff M, et al. Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. Am J Cardiol. 2003;92: 827-9. [PMID: 14516885]
37. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459-67. [PMID: 17242284]
38. Folsom AR, Kronmal RA, Detrano RC, O'Leary DH, Bild DE, Bluemke DA, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2008;168:1333-9. [PMID: 18574091] doi:10.1001/archinte.168.12.1333
39. Crouse JR 3rd, Grobbee DE, O'Leary DH, Bots ML, Evans GW, Palmer MK, et al; METEOR Study Group. Carotid intima-media thickness in low-risk individuals with asymptomatic atherosclerosis: baseline data from the METEOR study. Curr Med Res Opin. 2007;23:641-8. [PMID: 17355745]
40. Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol. 2004;24:1272-7. [PMID: 15059806]
41. Houslay ES, Cowell SJ, Prescott RJ, Reid J, Burton J, Northridge DB, et al; Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression trial Investigators. Progressive coronary calcification despite intensive lipidlowering treatment: a randomised controlled trial. Heart. 2006;92:1207-12. [PMID: 16449511]
42. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al; Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebocontrolled trial. Ann Intern Med. 2001;135:939-53. [PMID: 11730394]
43. Rumberger JA, Schwartz RS, Simons DB, Sheedy PF 3rd, Edwards WD, Fitzpatrick LA. Relation of coronary calcium determined by electron beam computed tomography and lumen narrowing determined by autopsy. Am J Cardiol. 1994;73:1169-73. [PMID: 8203333]
44. Nasir K, Raggi P, Rumberger JA, Braunstein JB, Post WS, Budoff MJ, et al. Coronary artery calcium volume scores on electron beam tomography in 12,936 asymptomatic adults. Am J Cardiol. 2004;93:1146-9. [PMID: 15110208]
45. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, et al. KEEPS: the Kronos Early Estrogen Prevention Study [Editorial]. Climacteric. 2005;8:3-12. [PMID: 15804727]
46. Selzer RH, Hodis HN, Kwong-Fu H, Mack WJ, Lee PL, Liu CR, et al. Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis. 1994;111:1-11. [PMID: 7840805]
47. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827-32. [PMID: 2407762]
48. Stanczyk FZ, Jurow J, Hsing AW. Limitations of direct immunoassays for measuring circulating estradiol levels in postmenopausal women and men in epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2010;19:903-6. [PMID: 20332268] doi:10.1158/1055-9965.EPI-10-0081
49. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28: 412-9. [PMID: 3899825]
50. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation. 1998;97:1784-90. [PMID: 9603532]
51. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-6. [PMID: 15033648]
52. Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 1996;101:627-34. [PMID: 9003110]
53. ARBITER-2: evidence that targeting HDL cholesterol slows atherosclerosis. Cardiovasc J S Afr. 2005;16:61. [PMID: 15778778]
54. Espeland MA, Applegate W, Furberg CD, Lefkowitz D, Rice L, Hunninghake D. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study. Am J Epidemiol. 1995;142:1011-9. [PMID: 7485045]
55. Liebson PR. ARBITER-6 HALTS and lipid concentrations and heart failure incidence: Framingham Heart Study. Prev Cardiol. 2010;13:141-4. [PMID: 20626670] doi:10.1111/j.1751-7141.2010.00069.x
56. Ostberg JE, Storry C, Donald AE, Attar MJ, Halcox JP, Conway GS. A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabolism. Clin Endocrinol (Oxf). 2007; 66:557-64. [PMID: 17371475]
57. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 1994;121:936-41. [PMID: 7978718]
58. Vehkavaara S, Hakala-Ala-Pietilä T, Virkamäki A, Bergholm R, Ehnholm C, Hovatta O, et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation. 2000;102:2687-93. [PMID: 11094033]
59. North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause. 2007;14:168-82. [PMID: 17259911]